Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Korean J Intern Med ; 36(3): 617-628, 2021 05.
Artigo em Inglês | MEDLINE | ID: mdl-33858123

RESUMO

BACKGROUND/AIMS: Although it is near concluded that renin-angiotensin system inhibitors do not have a harmful effect on coronavirus disease 2019 (COVID-19), there is no report about whether angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) offer any protective role. This study aimed to compare the association of ARBs and ACEIs with COVID-19-related mortality. METHODS: All patients with COVID-19 in Korea between January 19 and April 16, 2020 were enrolled. The association of ARBs and ACEIs with mortality within 60 days were evaluated. A comparison of hazard ratio (HR) was performed between COVID-19 patients and a retrospective cohort of pneumonia patients hospitalized in 2019 in Korea. RESULTS: Among 10,448 COVID-19 patients, ARBs and ACEIs were prescribed in 1,231 (11.7%) and 57 (0.6%) patients, respectively. After adjusting for age, sex, and history of comorbidities, the ARB group showed neutral association (HR, 1.034; 95% CI, 0.765 to 1.399; p = 0.8270) and the ACEI groups showed no significant associations likely owing to the small population size (HR, 0.736; 95% CI, 0.314 to 1.726; p = 0.4810). When comparing HR between COVID-19 patients and a retrospective cohort of patients hospitalized with pneumonia in 2019, the trend of ACEIs showed similar benefits, whereas the protective effect of ARBs observed in the retrospective cohort was absent in COVID-19 patients. Meta-analyses showed significant positive correlation with survival of ACEIs, whereas a neutral association between ARBs and mortality. CONCLUSION: Although ARBs or ACEIs were not associated with fatal outcomes, potential beneficial effects of ARBs observed in pneumonia were attenuated in COVID-19.


Assuntos
Antagonistas de Receptores de Angiotensina/uso terapêutico , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , COVID-19/diagnóstico , COVID-19/mortalidade , Hipertensão/tratamento farmacológico , Pneumonia Viral/mortalidade , Pneumonia/tratamento farmacológico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , COVID-19/complicações , Criança , Pré-Escolar , Estudos de Coortes , Feminino , Humanos , Hipertensão/complicações , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Pneumonia/diagnóstico , Pneumonia Viral/complicações , Sistema Renina-Angiotensina , República da Coreia/epidemiologia , Estudos Retrospectivos , SARS-CoV-2 , Adulto Jovem , Tratamento Farmacológico da COVID-19
3.
Japan Med Assoc J ; 58(4): 240-4, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27081619
4.
Japan Med Assoc J ; 57(4): 253-7, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-26005624
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...